CN113671187A - 一种用于检测mycn蛋白的ihc检测试剂盒 - Google Patents
一种用于检测mycn蛋白的ihc检测试剂盒 Download PDFInfo
- Publication number
- CN113671187A CN113671187A CN202110922034.6A CN202110922034A CN113671187A CN 113671187 A CN113671187 A CN 113671187A CN 202110922034 A CN202110922034 A CN 202110922034A CN 113671187 A CN113671187 A CN 113671187A
- Authority
- CN
- China
- Prior art keywords
- mycn
- ihc
- prognosis
- fish
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 title claims abstract description 65
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 title claims abstract description 65
- 238000001514 detection method Methods 0.000 title claims abstract description 25
- 101150022024 MYCN gene Proteins 0.000 claims abstract description 47
- 108700012912 MYCN Proteins 0.000 claims abstract description 46
- 238000004393 prognosis Methods 0.000 claims abstract description 36
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 230000005754 cellular signaling Effects 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000003149 assay kit Methods 0.000 claims 2
- 230000002055 immunohistochemical effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000013115 immunohistochemical detection Methods 0.000 abstract description 3
- 238000003364 immunohistochemistry Methods 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 238000002791 soaking Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000012188 paraffin wax Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 2
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及一种用于检测MYCN蛋白的IHC检测试剂盒,包括MYCN的蛋白杂交抗体。所述的MYCN的蛋白杂交抗体购自Cell Signaling Technology公司,货号为#84406s。本发明发现Cell Signaling Technology公司的货号是#84406s的MYCN的抗体可以用于神经母细胞瘤组织样本的免疫组化技术;其与FISH的吻合度在75%以上,与预后的吻合度较FISH的显著升高;其更有利于临床MYCN的检测与预后的判断;解决了国际上MYCN没有商业抗体进行免疫组化检测的问题。并且提高了其对MYCN的检测的精准性与对预后的判断性。
Description
技术领域
本发明涉及一种检测试剂盒,具体是一种用于检测MYCN蛋白的IHC(蛋白免疫组化)检测试剂盒。
背景技术
神经母细胞瘤是儿童最常见的颅外实体瘤,占儿童癌症死亡率约12%。其病程具有2极分化,一些病人不需要治疗可以自愈,一些病人经过各种治疗还是不能挽回生命。因此探寻预测预后的指标在儿童神经母细胞瘤中至关重要。神经母细胞瘤的MYCN扩增率约为22%,是神经母细胞瘤具有重要临床和预后价值的第一个遗传标记。目前国际神经母细胞瘤风险分组(INRG)和儿童肿瘤分组(COG)使用的分组指标中MYCN的扩增都占有很大分量。
迄今为止,由于缺乏可靠的MYCN的IHC抗体,临床和实验室检测方法主要局限于核酸水平,如常规聚合酶链式反应(PCR)、定量实时定量PCR(qRT-PCR)、半定量差异PCR(sq-PCR)、数字PCR(ddPCR)、荧光原位杂交(FISH)、染色体原位杂交(CISH)、多重连接依赖探针扩增(MLPA)等。目前已将FISH检测的MYCN基因状况整合到风险分类中。然而,一些研究已经证实,在DNA水平MYCN无扩增的病例中也可见MYCN蛋白的高表达,而DNA水平MYCN基因扩增的病人也有发现在蛋白水平表达不高的现象。即目前临床上广泛应用的MYCN的FISH检测,检测的是DNA水平的MYCN的COPY数,一般情况下,DNA水平COPY数高,RNA水平和蛋白水平会高。但还是有一定量的病人因为转录和翻译以及翻译后修饰,泛素化降解的问题,而不一致。从而影响其对预后的判定。
MYCN是在蛋白水平发挥其生物学效应,蛋白水平的检测,免疫组化检测时应用非常广泛的一个检测细胞内蛋白水平的方法。但很多MYCN的抗体灵敏性达不到,其与FISH结果以及预后的吻合度都很差,达不到用于临床的要求。因此寻找一种快速、可靠、经济的检测MYCN蛋白表达的方法具有重要意义。目前在国际上还没有一个MYCN的IHC商业抗体可以用于临床检测。
发明内容
本发明的目的是:提供了一种MYCN的蛋白杂交抗体作为儿童神经母细胞瘤的MYCN蛋白的IHC临床检测试剂中的应用。
本发明采用的技术方案为:
本发明提供了一种MYCN的蛋白杂交抗体作为儿童神经母细胞瘤的MYCN蛋白的临床检测试剂中的应用。在该应用中,所述试剂通过免疫组织化学检测样本中MYCN的表达水平。
进一步,所述的MYCN的蛋白杂交抗体购自Cell Signaling Technology公司,货号为#84406s。
进一步,在所述的应用中,所述的样本为组织样本。
本发明还提供了一种预测儿童神经母细胞瘤预后的IHC试剂盒,包括MYCN的蛋白杂交抗体。
进一步,所述的MYCN的蛋白杂交抗体购自Cell Signaling Technology公司,货号为#84406s。
进一步,所述的IHC试剂盒还包括二抗anti-rabbit-IgG,HRP linked,购自CellSignaling公司,货号为#7074。
本发明还提供了一种预测儿童神经母细胞瘤预后的试剂盒,包括上述IHC检测试剂盒和MYCN的FISH检测试剂盒。
本发明儿童神经母细胞瘤预后预测的判断方法为:
用兔抗MYCN抗体(#84406s,Cell Signaling Technology)免疫组织化学方法检测MYCN蛋白的表达。MYCN染色强度分级为0-3级(0=负,1=弱,2=中,3=强),阳性比例分级为0-4级(0为0%,1级为<25%,25%≤2级<50%,50%≤3级<75%,75%≤4级≤100%)。免疫组化分级由两位病理学家独立评分,取平均值,最终得分=染色强度*阳性比例。0分级为阴性,1-4分级为低表达,5-8分级为中位表达,9-12分级为高表达。
如果用FISH和免疫组化结合,诊断标准:
当该病人的FISH是阳性,IHC是在9以上(≥9),预示其预后不良,如果IHC在0-8之间,说明预后会好;如果该病人的FISH为阴性,IHC的值等于0,预后好,IHC大于0,预后差。
本发明其免疫组化评级用大于0和等于0,指导预后比用FISH显著准确;如果用FISH和免疫组化结合:FISH+的IHC小于9以及FISH-,IHC等于0的病人为一组,预后好,FISH+的IHC大于等于9,以及FISH-的IHC大于0的病人为一组,预后差。较单独利用FISH和免疫组化与预后更相关。
本发明所具有的有益效果:
本发明发现Cell Signaling Technology公司的货号是#84406s的MYCN的抗体(已公开的其商业应用技术领域为蛋白质印记,免疫沉淀,免疫荧光,流式细胞,染色质免疫沉淀技术),本发明发现其还可以用于神经母细胞瘤组织样本的免疫组化技术。其与FISH的吻合度在75%以上,与预后的吻合度较FISH的显著升高。其更有利于临床MYCN的检测与预后的判断。解决了国际上MYCN没有商业抗体进行免疫组化检测的问题。并且提高了其对MYCN的检测的精准性与对预后的判断性。
附图说明
图1.IHC与FISH结果的一致性比较,其中a)利用IHC检测MYCN蛋白表达并对结果进行综合评分;b)分析IHC和FISH检测MYCN表达的一致性;c-e)根据FISH检测结果(c、d)、INSS分期((c、d)和临床结局(e)对IHC结果进行归类分组。
图2联合IHC和FISH检测方法能更好的预测预后分析图;其中a-b)根据IHC结果分别对MYCN-amp(a)和MYCN-non(b)群体进行进一步分组及Kaplan-Meier生存分析;c)同时纳入FISH和IHC结果作为分组标准,并利用Kaplan-Meier生存分析比较各组间差异;d)利用色阶图谱归纳总结各临床因素与患者预后之间的关系(无*,表示P>0.05,差异不具有统计学意义,*表示P<0.05,**表示P<0.01,***表示P<0.001,****表示P<0.0001,差异具有统计学意义)。
具体实施方式
下面结合实施例对本发明作进一步说明,但不限定本发明的保护范围。
下列实施例中未注明具体条件的实验方法,均采用本技术领域常规技术,或按照生产厂商所建议的条件;所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
样本采集
2010年至2019年,病理检测证实有332名NB初诊患者于我院诊断治疗,其中有41名患者存在MYCN-amp。由于肿瘤样本保存时间过长导致肿瘤组织遭严重破坏、或肿瘤细胞过少,不利于蛋白检测等因素,仅28例MYCN-amp患者的肿瘤组织参与本试验。作为对照,我们另外选择了28名MYCN-non患者的肿瘤样本进行IHC检测,其中7名发生疾病相关死亡,19名患者末次随访时状态良好。所有患者确诊时年龄均不超过12岁,其中男性30例,女性26例。表3列出了患者年龄、性别、临床分期、危险分组、原发部位、FISH检测结果、MYCN免疫组化评分、预后、目前状态、随访时间等信息。按照伦理审查委员会规定的制度,每个病人在取样前均签署了知情同意书。
组织样本制备:
手术切出的肿瘤样本,半小时内切成小块,放在10%的***中固定,进行标准的石蜡包埋,切成2-3μm厚的薄片进行后续分析。
试验方法
1.IHC的实验方法
石蜡切片预处理:
a.室温保存的石蜡切片置65℃孵育1h,使石蜡熔化;
b.将切片依次于3个装有二甲苯的染缸内浸泡脱蜡,每次15min;
c.将切片依次于梯度酒精内浸泡复水:无水乙醇2次,3-5min/次;90%乙醇2次,3-5min/次;70%乙醇2次,3-5min/次;自来水1次,3min/次;
将切片置于3%H2O2内室温避光浸泡10min后,于自来水内室温浸泡5min;
将切片置于1×柠檬酸抗原修复液中,使用高火(98℃-100℃)微波加热至沸腾(可在染缸下垫纸,若纸巾浸湿即表示沸腾,一般约3min-4min),断电后于微波炉内静置10min;
从微波炉内取出染缸,冰上冷却至室温(注:期间勿打开染缸);
待柠檬酸抗原修复液冷却至室温后,取出切片,使用1×PBS洗片3次,3-5min/次;
用纸巾拭去多余液体,使用免疫组化笔在目标区域上画出疏水隔离区,滴加一抗(anti-MYCN,Cell Signaling公司,84406s,1:200稀释),于潮湿暗盒中4℃孵育过夜;将湿盒自4℃取出后,室温静置10min,使用1×PBS洗片3次,3-5min/次;
用纸巾拭去多余液体,滴加二抗(anti-rabbit-IgG,HRP linked,Cell Signaling公司,#7074,不用稀释),于室温内孵育20-25min;
使用1×PBS洗片3次,3-5min/次;
用纸巾拭去多余液体,滴加适量按比例配置的DAB显色剂,于室温内反应,显微镜下观察显色变化,适时于自来水中终止显色反应;
使用苏木素复染约1-2min、盐酸酒精分化1-2s后,于自来水中浸泡返蓝10-15min;
将切片依次于梯度酒精内浸泡脱水:70%乙醇2次,3-5min/次;90%乙醇2次,3-5min/次;无水乙醇2次,3-5min/次;
将切片依次于3个装有二甲苯的染缸内浸泡,每次5min;
将树胶与纯净二甲苯按照2:1比例稀释,作为封片剂封片,于室温下自然晾干玻片,至二甲苯完全挥发后可镜检。
2石蜡切片荧光免疫原位杂交(FISH),试剂盒名称LSI N-MYC SpectrumOrangeProbe:
1)石蜡切片预处理:
a.室温保存的石蜡切片置65℃孵育1h,使石蜡熔化;
b.将切片依次于3个装有二甲苯的染缸内浸泡脱蜡,每次15min;
c.将切片依次于梯度酒精内浸泡复水:无水乙醇2次,3-5min/次;90%乙醇2次,3-5min/次;70%乙醇2次,3-5min/次;
d.将切片置于0.2M HCl内,室温孵育10min;
e.使用1×PBS洗片3次,3-5min/次;
f.将切片置于0.01M枸橼酸盐缓冲液(PH=6.0)内80℃孵育1h;
g.使用2×SSC缓冲液洗片2次,3-5min/次;
h.使用DDW洗片,3-5min/次;
i.将0.5mg/ml pepsin及0.02M HCl溶液于37℃内预热5min后按1:1等比例混合,配制为0.25mg pepsin/ml 0.01M盐酸溶液;
j.在切片上滴加300μl pepsin/HCL溶液,盖上盖玻片,37℃孵育10min;
k.使用2×SSC缓冲液洗片2次,3-5min/次;
l.使用0.4%多聚甲醛室温固定切片10min;
m.使用1×PBS洗片3次,3-5min/次;
n.将切片依次于梯度酒精内浸泡脱水:70%乙醇2次,3-5min/次;90%乙醇2次,3-5min/次;无水乙醇2次,3-5min/次
o.于室温下自然晾干玻片;
2)探针预处理:
将探针于75℃孵育5min后立即置于0℃内5-10min,使双链DNA探针变性;
3)杂交:
在已变性脱水的切片上滴加10μl探针混合液,盖上盖玻片,封片后置于潮湿暗盒中37℃杂交过夜(约15-17h);
4)洗脱:
a.次日,将切片取出后轻轻揭下盖玻片,放入4×SSPE中,47℃孵育5min;
b.再次将玻片放于4×SSPE中,55-72℃孵育10min;
c.将切片依次于梯度酒精内浸泡脱水:70%乙醇2次,3-5min/次;90%乙醇2次,3-5min/次;无水乙醇2次,3-5min/次;
d.将切片放入己烷/异丙醇混合液内室温浸泡10min(己烷:异丙醇按6:4比例混合);
e.将切片放入异丙醇内室温浸泡5min;
f.将切片放入无水乙醇内室温浸泡5min;
g.于室温下自然晾干玻片至乙醇完全挥发;
h.使用DAPI复染后盖上盖玻片,轻轻挤压出多余液体,封片后4℃避光保存;
2MYCN表达水平的判定
1)MYCN免疫组化(IHC)评分:
①MYCN染色强度分为0-3分,其中0=阴性,1=弱,2=中,3=强;
②MYCN染色阳性比例分为0-4分,其中0%=0分,<25%=1分,25%≤2分<50%,50%≤3分<75%,75%≤4分≤100%;
③最终评分=染色强度×阳性比例。0分为“阴性”,1-4分为“低表达”,5-8分为“中位表达”,9-12分为“高表达”。
2)MYCN的FISH结果判定
MYCN/PAX3比值>5为阳性,即MYCN扩增;MYCN/PAX3比值≤1为阴性,即MYCN非扩增
实验结果
1检测本发明IHC检测所用抗体的有效性:
为验证在本发明中所用抗体(MYCN#84406s,Cell Signaling)的有效性,我们纳入更多的样本(n=56)进行IHC检测。实验所用肿瘤样本均经FISH检测,其中1/2确诊为MYCN-amp(表1)。结果显示,不同肿瘤组织间,在恶性细胞阳性比例和染色强度方面存在较大差异。为了便于后续分析,我们基于以上两点对染色结果进行综合评分(图1a)。在此基础上,我们对FISH和IHC结果的一致性进行了分析(表2)。结果显示,无论MYCN-amp与否,≥75%的IHC结果与FISH结果一致(表4,图1b)。而对于两种检测结果不一致的患者,我们纳入患者的临床信息进行综合分析,以确认哪种方法与预后更加相关(为了确保个人预后的准确性,涉及到随访时间时,我们只纳入2016年及之前确诊的患者)。结果显示,IHC评分随INSS分期升高而升高,并与患者临床预后高度相关(图1c-e)。在MYCN-amp患者中,11例MYCN蛋白高表达(IHC评分≥9)患者中7例预后不良,而5例无表达或低表达患者均无不良事件发生;在MYCN-non患者中,所有(4例)检测到MYCN蛋白表达的患者均预后不良,而17例预后良好的患者,均无MYCN蛋白表达(表3)。所有这些数据均表明,该MYCN抗体具有良好的灵敏度和特异性,与FISH结果具有较高的一致性,而对于FISH未检出的患者,IHC具有补充作用,能提高MYCN检出率,临床应用价值大。
表1患者临床信息
性别:0=女;1=男;
危险分级:1=低危;2=中危;3=高危;4=极高危;
原发部位:1=颈部;2=胸部;3=腹部;4=盆腔;
CR:完全缓解(complete remission)
表2本次实验中,IHC与FISH结果的一致性比较
表3 MYCN蛋白表达与临床预后的相关性分析
2联合IHC和FISH检测方法能更好的预测预后
根据前期结果可以看出,IHC能更准确的检测MYCN在肿瘤中的表达以及预测预后。为了进一步证明这一点,利用IHC结果对MYCN-amp和MYCN-non群体进行进一步分组,并利用Kaplan-Meier生存分析进行统计分析。结果发现,IHC结果可进一步区分MYCN-amp和MYCN-non群体的预后情况(图2a-b)。此外,如果我们仅纳入FISH结果作为分组依据,MYCN-amp和MYCN-non的无事件生存率分别为是56.2%和63.0%,生存分析显示两组间没有统计学差异。而只纳入IHC结果作为分组依据,两组间生存率差异具有统计学意义(图2c)。结合两种方法,即将FISH+IHC<9、FISH-IHC=0作为一组,FISH+IHC≥9、FISH-IHC>0作为另一组,则可以达到最佳临床预测效果(图2c)。同时,我们发现如果FISH检测提示MYCN-non,但如果IHC可检测到MYCN蛋白表达,此患者多预后不佳;相反,FISH检测提示MYCN-amp,而IHC无法检测到MYCN蛋白表达或仅为低表达,此患者多预后良好(图2d)。综上所述,IHC可以弥补FISH在评估预后和指导治疗方面的不足,两种检测结果联合分析可达到最佳临床预测效果。
Claims (7)
1.一种MYCN的蛋白杂交抗体作为儿童神经母细胞瘤的MYCN蛋白的IHC临床检测试剂中的应用。
2.根据权利要求1所述的应用,其特征在于:所述的MYCN的蛋白杂交抗体购自CellSignaling Technology公司,货号为#84406s。
3.根据权利要求1或2所述的应用,其特征在于:在所述的应用中,所述的样本为组织样本。
4.一种预测儿童神经母细胞瘤预后的IHC试剂盒,其特征在于:包括MYCN的蛋白杂交抗体。
5.根据权利要求4所述的一种预测儿童神经母细胞瘤预后的IHC试剂盒,其特征在于:所述的MYCN的蛋白杂交抗体购自Cell Signaling Technology公司,货号为#84406s。
6.根据权利要求5所述的一种预测儿童神经母细胞瘤预后的IHC试剂盒,其特征在于:所述的IHC试剂盒还包括二抗anti-rabbit-IgG,HRP linked,购自Cell Signaling公司,货号为#7074。
7.一种预测儿童神经母细胞瘤预后的试剂盒,其特征在于:包括MYCN的FISH检测试剂盒和权利要求5-6所述IHC检测试剂盒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110922034.6A CN113671187A (zh) | 2021-08-12 | 2021-08-12 | 一种用于检测mycn蛋白的ihc检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110922034.6A CN113671187A (zh) | 2021-08-12 | 2021-08-12 | 一种用于检测mycn蛋白的ihc检测试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113671187A true CN113671187A (zh) | 2021-11-19 |
Family
ID=78542432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110922034.6A Pending CN113671187A (zh) | 2021-08-12 | 2021-08-12 | 一种用于检测mycn蛋白的ihc检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113671187A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009141440A1 (en) * | 2008-05-21 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma |
US20100105868A1 (en) * | 2008-10-27 | 2010-04-29 | Johji Inazawa | Method for detecting neuroblastoma |
CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
-
2021
- 2021-08-12 CN CN202110922034.6A patent/CN113671187A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009141440A1 (en) * | 2008-05-21 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma |
US20100105868A1 (en) * | 2008-10-27 | 2010-04-29 | Johji Inazawa | Method for detecting neuroblastoma |
CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
Non-Patent Citations (3)
Title |
---|
HSIU-HAO CHANG等: "The prognostic roles of and correlation between ALK and MYCN protein expression in neuroblastoma", 《JOURNAL OF CLINICAL PATHOLOGY》, vol. 73, no. 3 * |
刘方杰;何晓燕;谭正兰;邹琳;: "miR-221对神经母细胞瘤细胞SH-SY5Y裸鼠移植瘤生长的影响", 第三军医大学学报, no. 15 * |
吕凡;邬文杰;张弛;吴晔明;: "MYCN基因表达变化增强神经母细胞瘤细胞SK-N-BE(2)凋亡", 中国肿瘤临床, no. 15 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression | |
US20070037173A1 (en) | Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients | |
EP1597353A2 (en) | CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS | |
CN110187110B (zh) | 一种贲门癌预后预测标志物及其应用 | |
KR102384848B1 (ko) | 방광암용 바이오마커로서의 케라틴 17 | |
CN110244058B (zh) | Enpp1在制备高级别浆液性卵巢癌诊断及预后试剂盒中的应用 | |
US20230204585A1 (en) | Histochemical systems and methods for evaluating egfr and egfr ligand expression in tumor samples | |
Innaro et al. | Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology | |
CN116559462A (zh) | 用于肿瘤患者预后的生物标志物组及其用途 | |
WO2013033933A1 (zh) | 用于测评卵巢癌原发化疗敏感性的试剂盒、方法及应用 | |
CN113671187A (zh) | 一种用于检测mycn蛋白的ihc检测试剂盒 | |
CN111323604B (zh) | 一组贲门腺癌预后预测标志物及其应用 | |
CN111665358B (zh) | Nalcn蛋白在食管鳞癌预后预测中的应用 | |
CN111551545B (zh) | 一种用于食管癌高危人群早期筛查的液体活检elisa试剂盒 | |
US20230375551A1 (en) | Methods for confirming detection and evaluating the progression of a prostate cancer and related therapies | |
CN110244057B (zh) | Adora3在制备高级别浆液性卵巢癌诊断及预后试剂盒中的应用 | |
CN109709333B (zh) | H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用 | |
US9523690B2 (en) | Biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma | |
CN113504370B (zh) | Mapk15蛋白在***癌的恶性程度或预后程度预测中的应用 | |
US20170029898A1 (en) | Novel method for screening for prostate cancer | |
EP2607493A1 (en) | Diagnosis of steatohepatitis | |
CN113640517B (zh) | Bub1蛋白在制备高级别脑膜瘤预后评估试剂或试剂盒中的应用 | |
CN110221072B (zh) | 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用 | |
CN114295839B (zh) | Hoxb7蛋白在制备用于鉴别少突胶质细胞瘤和星形细胞瘤的试剂盒中的应用 | |
CN117092342A (zh) | Chd4蛋白在食管鳞癌预后预测中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |